NADAC acquisition cost data for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE). This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00378204501 | $0.1891 | 2022-12-21 | Rx |
| 00781210201 | $0.1891 | 2022-12-21 | Rx |
| 00904662361 | $0.1891 | 2022-12-21 | Rx |
| 16714009801 | $0.1891 | 2022-12-21 | Rx |
| 16729004101 | $0.1891 | 2022-12-21 | Rx |
| 51079081701 | $0.1891 | 2022-12-21 | Rx |
| 51079081720 | $0.1891 | 2022-12-21 | Rx |
| 55111052501 | $0.1891 | 2022-12-21 | Rx |
| 64380072006 | $0.1891 | 2022-12-21 | Rx |
| 67877027801 | $0.1891 | 2022-12-21 | Rx |
Generic: Tacrolimus | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $75.2M | 372,291 | 119,454 | $2.28 |
| 2020 | $104.5M | 448,510 | 133,950 | $2.38 |
| 2021 | $101.8M | 468,258 | 155,736 | $2.28 |
| 2022 | $107.1M | 491,782 | 172,443 | $2.37 |
| 2023 | $103.3M | 535,062 | 204,385 | $2.21 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.